Advancing Type 1 Diabetes Management: Integrating Novel Therapies, Technologies, and Adjunctive Approaches
GLP-1 Compounding Controversy: What Med Spa Owners Need to Know Key Takeaways The regulatory environment for compounded weight loss medications remains fluid, with FDA decisions creating uncertainty for med spa owners and their patients
Beyond weight outcomes, the Phase 2 obesity trial also reported improvements in several cardiometabolic markers, including: Reductions in waist circumference Improvements in fasting glucose and insulin sensitivity Favourable changes in blood pressure and lipid profiles Phase 3 trials understood to form part of the TRIUMPH programme are now underway, evaluating retatrutide in broader populations including people with type 2 diabetes and cardiovascular disease
Your healthcare team may submit a report to the MHRA Yellow Card Scheme, which collects data on pregnancy outcomes after exposure to GLP-1 medicines
However, toxins such as environmental pollutants, drugs, and chemicals in food can impair the methylation pathway by interfering with the enzymes involved in the process and depleting the body's stores of crucial components like SAMe and methionine
